CTI BioPharma Corp. CTIC
Set alert
9.10 0.00 0.00%
As of Jun 23, 3:58 PM ET
9.09 Day range 9.10
52-week range unavailable
- Open
- 9.10
- Prev close
- 9.10
- Mkt cap
- 1.20B
- Vol
- 5.56M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.09
- High
- 9.10
- Forward P/E
- 101.00
- Beta
- 0.83
- Short ratio
- 1.08
- Inst. own
- 83.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2023
- 50-d avg
- 7.63
- 200-d avg
- 5.87
- 1y target
- 10.37
2Y chart
Events in this range
- Mar 31, 2022Earnings: —; estimate -0.28; surprise —%
- May 12, 2022Earnings: —; estimate -0.35; surprise —%
- Aug 8, 2022Earnings: —; estimate -0.2; surprise —%
- Nov 7, 2022Earnings: —; estimate -0.15; surprise —%
- Mar 6, 2023Earnings: —; estimate -0.09; surprise —%
- Apr 19, 2023Rating: Needham · — → Buy
- May 11, 2023Downgrade: Needham · Buy → Hold
- May 11, 2023Downgrade: JMP Securities · Market Outperform → Market Perform
- May 15, 2023Downgrade: Stifel · Buy → Hold
- May 16, 2023Downgrade: SVB Leerink · Outperform → Market Perform
- May 24, 2023Rating: JMP Securities · — → Market Perform
Signals (87)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | May 31, 2023 | 3 years ago |
| SMA: Bullish | May 10, 2023 | 3 years ago |
| MACD: Buy Signal | May 10, 2023 | 3 years ago |
| RSI: Overbought | May 10, 2023 | 3 years ago |
| MACD: Sell Signal | May 9, 2023 | 3 years ago |
| SMA: Bullish | Apr 19, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 27, 2023 | 3 years ago |
| RSI: Oversold | Mar 22, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 6, 2023 | 3 years ago |
| RSI: Oversold | Mar 6, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 23, 2023 | 3 years ago |
| SMA: Bearish | Feb 3, 2023 | 3 years ago |
| SMA: Bearish | Feb 3, 2023 | 3 years ago |
| SMA: Bullish | Feb 2, 2023 | 3 years ago |
| SMA: Bullish | Feb 2, 2023 | 3 years ago |
| SMA: Bearish | Jan 30, 2023 | 3 years ago |
| SMA: Bearish | Jan 30, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Jan 20, 2023 | 3 years ago |
| SMA: Bearish | Jan 18, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 13, 2023 | 3 years ago |
| SMA: Bullish | Jan 12, 2023 | 3 years ago |
| SMA: Bullish | Jan 12, 2023 | 3 years ago |
| SMA: Bearish | Jan 4, 2023 | 3 years ago |
| SMA: Bearish | Jan 4, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 4, 2023 | 3 years ago |
| MACD: Buy Signal | Dec 30, 2022 | 3 years ago |
| SMA: Bearish | Dec 27, 2022 | 3 years ago |
| SMA: Bullish | Dec 20, 2022 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 5, 2022 | 3 years ago |
| SMA: Bullish | Nov 16, 2022 | 3 years ago |
| SMA: Bearish | Nov 15, 2022 | 3 years ago |
| SMA: Bullish | Nov 8, 2022 | 3 years ago |
| SMA: Bullish | Nov 8, 2022 | 3 years ago |
| SMA: Bearish | Nov 7, 2022 | 3 years ago |
| SMA: Bullish | Nov 1, 2022 | 4 years ago |
| SMA: Bearish | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Oct 28, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 27, 2022 | 4 years ago |
| SMA: Bearish | Oct 19, 2022 | 4 years ago |
| SMA: Bullish | Oct 17, 2022 | 4 years ago |
| SMA: Bearish | Oct 14, 2022 | 4 years ago |
| SMA: Bullish | Oct 13, 2022 | 4 years ago |
| SMA: Bearish | Oct 12, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 7, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 3, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 16, 2022 | 4 years ago |
| SMA: Bearish | Sep 15, 2022 | 4 years ago |
| SMA: Bullish | Sep 14, 2022 | 4 years ago |
| SMA: Bearish | Sep 13, 2022 | 4 years ago |
| SMA: Bullish | Sep 7, 2022 | 4 years ago |
| SMA: Bearish | Sep 6, 2022 | 4 years ago |
| SMA: Bullish | Aug 31, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 24, 2022 | 4 years ago |
| SMA: Bullish | Aug 23, 2022 | 4 years ago |
| SMA: Bearish | Aug 10, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 9, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 1, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 18, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 7, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 23, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 22, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 21, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 17, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 14, 2022 | 4 years ago |
| MACD: Buy Signal | May 23, 2022 | 4 years ago |
| SMA: Bullish | May 19, 2022 | 4 years ago |
| SMA: Bearish | May 9, 2022 | 4 years ago |
| MACD: Sell Signal | May 6, 2022 | 4 years ago |
| MACD: Buy Signal | May 2, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 28, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 26, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 31, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 25, 2022 | 4 years ago |
| RSI: Overbought | Mar 25, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 21, 2022 | 4 years ago |
| RSI: Overbought | Mar 2, 2022 | 4 years ago |
| SMA: Bullish | Mar 1, 2022 | 4 years ago |
| SMA: Bearish | Feb 28, 2022 | 4 years ago |
| SMA: Bullish | Feb 14, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 9, 2022 | 4 years ago |
| SMA: Bearish | Jan 21, 2022 | 4 years ago |
| SMA: Bullish | Jan 20, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 10, 2022 | 4 years ago |
| RSI: Oversold | Dec 1, 2021 | 4 years ago |
Key statistics
- Market cap
- 1.20B
- Enterprise value
- 1.26B
- Trailing P/E
- 0.00
- Forward P/E
- 101.00
- PEG ratio
- 0.00
- Price / sales
- 15.82
- Price / book
- 0.00
- EPS (TTM)
- -0.54
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -91.38%
- Revenue (TTM)
- 75.77M
- Revenue growth
- 950.80%
- Free cash flow
- -85.26M
- Total cash
- 59.01M
- Total debt
- 118.29M
- Return on equity
- 0.00%
- Shares outstanding
- 131.88M
- Short % of float
- 15.18%
- 50-day average
- 7.63
- 200-day average
- 5.87
Analyst view
Consensus: buy
Buy
Price target (mean) 10.37 +14.0% upside
Now 9.10
- Target (low)
- 9.00
- Target (mean)
- 10.37
- Target (high)
- 13.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate -0.08.
Financials — quick view
CTIC Revenue — quarterly 24.12M
CTIC Net income — quarterly -13.42M
CTIC EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 14, 2023 | Jun 1, 2023 | -0.08 | — | — | — |
| Mar 6, 2023 | Dec 1, 2022 | -0.09 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.15 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.20 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.35 | — | — | — |
| Mar 31, 2022 | Dec 1, 2021 | -0.28 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 24, 2023 | JMP Securities | main | — | Market Perform |
| May 16, 2023 | SVB Leerink | down | Outperform | Market Perform |
| May 15, 2023 | Stifel | down | Buy | Hold |
| May 11, 2023 | JMP Securities | down | Market Outperform | Market Perform |
| May 11, 2023 | Needham | down | Buy | Hold |
| Apr 19, 2023 | Needham | reit | — | Buy |
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ctibiopharma.com
News
- Sobi completes acquisition of CTI BioPharma Corp.
- Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
- CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
- CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
- Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
- Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
- CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
- CTI BioPharma skyrockets on acquisition by Sobi
- Why Shares of CTI BioPharma Are Soaring Wednesday
- Shareholder Alert: Ademi LLP investigates whether CTI BioPharma Corp. has obtained a Fair Price in its transaction with Sobi
Your note
Sign in to keep a note on CTIC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BVF PARTNERS L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 8, 2022 | 0 |
| CRAIG ADAM R | Chief Executive Officer | Sale | Jan 23, 2023 | 29,440 |
| FONG JAMES K | Officer | Sale | Jan 23, 2023 | 3,565 |
| KIRSKE DAVID H. SR | Chief Financial Officer | Sale | Jan 2, 2023 | 17,127 |
| LOVE RICHARD L | Director | Sale | Sep 28, 2017 | 73,718 |
| METZGER MICHAEL A | Director | Sale | Nov 7, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| State Street Corporation | 9.43% | 12,437,278 | 113.05M | Mar 30, 2023 |
| Rubric Capital Management LP | 6.80% | 8,963,256 | 81.48M | Mar 30, 2023 |
| BVF Inc. | 6.68% | 8,813,021 | 80.11M | Mar 30, 2023 |
| Blackrock Inc. | 5.39% | 7,102,626 | 64.56M | Mar 30, 2023 |
| Stonepine Capital Management, LLC | 4.96% | 6,535,674 | 59.41M | Mar 30, 2023 |
| Marshall Wace LLP | 4.52% | 5,960,103 | 54.18M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.47% | 12,486,890 | 113.51M | Feb 27, 2023 |
| Vanguard Total Stock Market Index Fund | 2.64% | 3,484,904 | 31.68M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.69% | 2,228,127 | 20.25M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 1.02% | 1,346,944 | 12.24M | Dec 30, 2022 |
| Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh | 0.87% | 1,153,365 | 10.48M | Mar 30, 2023 |
| TIAA-CREF Funds-Quant Small Cap Equity Fund | 0.75% | 988,140 | 8.98M | Jan 30, 2023 |